Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

 KYMR – Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.
KYMR
$47.71
Name : Kymera Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,106,855,936.00
EPSttm : -3.11
finviz dynamic chart for KYMR
Kymera Therapeutics, Inc.
$47.71
0.10%
$0.05

Float Short %

13.14

Margin Of Safety %

Put/Call OI Ratio

0.68

EPS Next Q Diff

-0.11

EPS Last/This Y

-0.62

EPS This/Next Y

-0.4

Price

47.66

Target Price

62.32

Analyst Recom

1

Performance Q

46.47

Relative Volume

1.55

Beta

2.07

Ticker: KYMR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07KYMR29.060.400.333345
2025-05-08KYMR30.710.400.003345
2025-05-09KYMR30.090.401.003345
2025-05-12KYMR32.170.400.333341
2025-05-13KYMR31.140.400.003341
2025-05-14KYMR29.720.400.003341
2025-05-15KYMR30.30.396.003323
2025-05-16KYMR30.270.39999.993325
2025-05-19KYMR29.960.501.502688
2025-05-20KYMR31.430.501.002713
2025-05-21KYMR30.140.500.182715
2025-05-22KYMR30.160.500.132726
2025-05-23KYMR29.250.502.002734
2025-05-27KYMR28.140.503.002737
2025-05-28KYMR28.560.510.072753
2025-05-29KYMR30.270.501.002769
2025-05-30KYMR29.670.500.002773
2025-06-02KYMR43.120.501.352782
2025-06-03KYMR43.580.610.933249
2025-06-04KYMR44.280.644.003921
2025-06-05KYMR47.690.680.714044
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07KYMR29.11-47.6-63.7-3.73
2025-05-08KYMR30.70-47.6-76.3-3.73
2025-05-09KYMR30.07-47.6-49.3-3.73
2025-05-12KYMR32.17-47.6-81.4-3.73
2025-05-13KYMR31.14-47.6-29.8-3.73
2025-05-14KYMR29.75-48.0-25.3-3.66
2025-05-15KYMR30.00-48.0-40.6-3.66
2025-05-16KYMR30.27-48.9-41.2-3.65
2025-05-19KYMR30.20-48.9-37.1-3.65
2025-05-20KYMR31.44-48.9-51.9-3.65
2025-05-21KYMR30.12-48.9-23.5-3.65
2025-05-22KYMR30.18-49.4-38.4-3.63
2025-05-23KYMR29.47-49.4-29.7-3.63
2025-05-27KYMR28.14-49.4-21.9-3.63
2025-05-28KYMR28.77-49.4-45.6-3.63
2025-05-29KYMR30.27-49.4-55.5-3.63
2025-05-30KYMR29.64-49.4-30.8-3.63
2025-06-02KYMR43.07-49.4-194.5-3.63
2025-06-03KYMR43.58-48.2-41.1-3.60
2025-06-04KYMR44.29-48.2-42.9-3.60
2025-06-05KYMR47.66-48.2-62.4-3.60
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07KYMR-0.194.2413.79
2025-05-08KYMR-0.194.2413.79
2025-05-09KYMR-0.194.2413.79
2025-05-12KYMR-0.194.5913.45
2025-05-13KYMR-0.194.5913.45
2025-05-14KYMR-0.194.5913.41
2025-05-15KYMR-0.194.5913.45
2025-05-16KYMR-0.194.5913.45
2025-05-19KYMR-0.185.6913.51
2025-05-20KYMR-0.185.6913.51
2025-05-21KYMR-0.185.6913.51
2025-05-22KYMR-0.185.6913.51
2025-05-23KYMR-0.215.6913.51
2025-05-27KYMR-0.212.3713.50
2025-05-28KYMR-0.212.3713.14
2025-05-29KYMR-0.212.3713.14
2025-05-30KYMR-0.212.3713.14
2025-06-02KYMR-0.212.7313.14
2025-06-03KYMR-0.192.7313.14
2025-06-04KYMR-0.632.7313.14
2025-06-05KYMR-0.632.7313.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.82

Avg. EPS Est. Current Quarter

-0.86

Avg. EPS Est. Next Quarter

-0.93

Insider Transactions

-0.63

Institutional Transactions

2.73

Beta

2.07

Average Sales Estimate Current Quarter

17

Average Sales Estimate Next Quarter

13

Fair Value

Quality Score

28

Growth Score

27

Sentiment Score

96

Actual DrawDown %

48.2

Max Drawdown 5-Year %

Target Price

62.32

P/E

Forward P/E

PEG

P/S

52.71

P/B

3.95

P/Free Cash Flow

EPS

-3.1

Average EPS Est. Cur. Y​

-3.6

EPS Next Y. (Est.)

-4

Target Price Estimates Raised

4

Target Price Estimates Lowered

Profit Margin

-409.07

Relative Volume

1.55

Return on Equity vs Sector %

-54.6

Return on Equity vs Industry %

-36.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.14

EBIT Estimation

-62.4
Kymera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 208
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
stock quote shares  KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today  KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history  KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading